Comparing pain relief between dexmedetomidine and dexamethasone with ropivacaine after costotransverse block in patients undergoing breast surgeries.
Phase 4
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2023/04/051463
- Lead Sponsor
- Department of Anaesthesia and Intensive care
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
American Society of Anesthesiologists (ASA) class I-II
Age more than 18 years at the date of inclusion
Females posted for breast surgery
Who have received thorough information and have signed the informed written consent form
Exclusion Criteria
Patient refusal
ASA III- IV including patient with severe respiratory,cardiovascular, liver and metabolic or pre-existing neurological deficit
Skin infection at puncture site
Allergy to study drugs
Recent history of use of analgesic/steroid drugs
Pregnant patient
History of psychiatric illness and substance abuse.
Morbid obesity BMI >40 kg/m2
Coagulation abnormalities (INR >1.5,thrombocytopenia)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the efficacy of dexmedetomidine <br/ ><br>versus dexamethasone as an adjuvant to <br/ ><br>ropivacaine on pain relief after costotransverse <br/ ><br>block by determining the quality of recovery assessed using Quality of Recovery(QoR-15) scale at 24 hour post operatively.Timepoint: At 24 hrs.
- Secondary Outcome Measures
Name Time Method To determine the time for first requirement of analgsia. <br/ ><br>Total cumulative dose of rescue analgesic <br/ ><br>(tramadol) consumption in the 24 h after surgery. <br/ ><br>VAS scores at rest and on arm movements. <br/ ><br>Patient satisfaction with block. <br/ ><br>Future willingness to undergo repeat peripheral nerve block. <br/ ><br>Note any side effects.Timepoint: 1hr, 4hr, 8hr, 12hr, 24hr.